Clinigen Group (OTCMKTS:CLIGF) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Clinigen Group (OTCMKTS:CLIGF) from a sell rating to a hold rating in a research note released on Tuesday, Zacks.com reports.

According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

CLIGF stock opened at $12.90 on Tuesday. The firm has a 50-day moving average of $12.90. Clinigen Group has a 1 year low of $9.87 and a 1 year high of $12.90.

Read More: Exchange-Traded Funds (ETFs)

Get a free copy of the Zacks research report on Clinigen Group (CLIGF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.